Hepatobiliary&Pancreatic Diseases International

General information

Hepatobiliary&Pancreatic Diseases International is a journal published bimonthly in the English language by the First Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou, China. We welcome original research articles,review articles,editorials,and others from any part of the world. Manuscripts are reviewed by members of the international editorial board and our expert peer reviewers,then either accepted for publication or rejected by the chief editor.Manuscripts should be submitted via https://mc03.manuscriptcentral.com/hbpdint.

Most of submissions accepted for publication may undergo revisions recommended by the reviewers, editors or statistical advisers.A decision takes from two weeks to three months,the longer period being due to the multiple reviews needed for articles likely to be accepted.Publication varies from two to six months after final acceptance.Proofs of edited articles and illustrations are sent to the corresponding author for correction and reply to any queries from editors.A sample copy of the journal containing the articles will be forwarded to the corresponding author within a few days of publication.

Online submissions

Original research articlesincluding randomized trials, intervention studies,studies of screening and diagnostic tests,cohort studies,cost-effectiveness analyses and case control studies should be prepared in accordance with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals(www.icmje.org).Those of randomized controlled trials(RCTs)should follow the CONSORT statement(www.consort-statement.org).The reporting of other articles should follow the guidelines set by the different initiatives or groups listed in the appendix.The article should be submitted with two separate files,one with detailed information about authors and the title,short running title,source of the work,in addition to the names,address,telephone and fax number or E-mail address for the corresponding author.Another file should show only the title,running title,abstract,main text,tables,figures of the submitted article as well as a list of references,which will be sent to reviewers.

The authors'names(normally no more than six)and their initials should be in the same form as in their other publications with one major qualification such as MD or PhD,their current appointment and a full postal address.One author should be named for editorial correspondence.

Each submission must be accompanied by a letter of copyright transfer signed by all the authors(see the detailed description in the last section)and other relevant documents including informed consent obtained from research subjects and research approval from the supervising or institutional ethics bodies.Author(s)of each submission should clarify the functions in or contributions to their research and declare,if any,competing interest.A choice of one of the following statements will be requested when a decision has been made to accept the paper:

1.The author or one or more of the authors have received or will receive benefits for personal or professional use from a commercial party related directly or indirectly to the subject of this article.

2.No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

3.The author or authors do not choose to declare any conflict of interest related directly or indirectly to the subject of this article.

The statements selected by the author or authors will be published with the article.The signature of each author will be required.No article will be published until the completed form has been received at the Hepatobiliary&Pancreatic Diseases International office.

Manuscripts should be prepared with generous margins, and double spacing is essential throughout the text,the references and the captions.Tables,figures,captions and list of references should appear properly in the text.The style should be simple and direct,free from ambiguity and jargon,and with minimal use of abbreviations.

Thetitleof the paper should be chosen with care:a short one has more impact and may be expanded by a subtitle.

Structured abstractof original articles should include four sections as Background, Methods, Results and Conclusions and have no more than 300 words summarizing the most important points in the article,incorporating key words suitable for electronic retrieval systems.Background:This section should provide a precise statement of the primary focus of the study and the context in which it was carried out.Methods:This section describes how the study was performed,including details of clinical and/or technical procedures.Results:This section describes the salient results of the study.Conclusions:This section covers conclusions and their clinical application or others,while equal emphasis should be given to positive and negative findings of equal scientific merit.

Themain textshould be divided under headings.For many research papers the best sequence is Introduction,Methods(Materials or Patients),Results,and Discussion.The text should comment on,but should not repeat,the details given in tables,figures or captions.Any acknowledgements should be made at the end of the main text.

Introduction:This should explain the problem which is to be addressed, with a definition of the hypothesis to be examined if appropriate,out-lining,briefly,its relevance to the appropriate literature.

Methods(Materials or Patients):The subjects of the study and the methods employed in the investigation must be clearly described.For example,the reasons for examining the particular group of patients should be made clear,and reasons for exclusion of individuals from the study must be stated.Any group used as controls must be defined accurately.

Ethical approval of studies and informed consent are required.For all manuscripts reporting data from studies involving human participants or animals,formal review and approval,or formal review and waiver,by an appropriate institutional review board or ethics committee is required and should be described in the Methods section. For those investigators who do not have formal ethics review committees,the principles outlined in the Declaration of Helsinki should be followed.For investigations of humans,state in the Methods section the manner in which informed consent was obtained from the study participants(i.e.,oral or written).Editors may request that authors provide documentation of the formal review and recommendation from the institutional review board or ethics committee responsible for oversight of the study.

Results:These must be clearly expressed in simple language.Tables or similar diagrams can be used but must not duplicate material already described in the text.

Discussion:This section must be succinct, pointing out the relevance of the work described in the article and its contribution to current knowledge.The results must be interpreted clearly,and both strength and weakness expressed.Discussion of pertinent references must be concise and short.

Each of thetablesshould have a short descriptive heading.

Thereferencesin the text should include only those that are important and have been studied fully by the authors.The authors are responsible for the accuracy and completeness of the cited references and for correct citation of the text.When listing references the names of journals should be abbreviated according to Index Medicus(List all authors and/or editors up to 6;if more than 6,list the first 6 and et al).All references will be checked deliberately by the authors;PMID roots in the abstract serial number indexed by PubMed(http://www.ncbi.nlm.nih.gov/sites/entrez?db=PubMed)and doi are requested.The references cited should be represented in the text by numbers within square brackets in the order of their appearance.The list of references at the end of the text should be in this numerical order with details and punctuation as follows:

Article from journal—more than one author

Cen C,Fang HX,Yu SF,Liu JM,Liu YX,Zhou L,et al.Association between ADIPOQ gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation.Hepatobiliary Pancreat Dis Int 2017;16:602-609. PMID: 29291779 doi: 10.1016/S1499-3872(17)60069-9.

Article from journals with English abstracts only

Sun JH,Zhang YL,Nie CH,Li J,Zhou TY,Zhou GH,et al.Effect of liver cirrhosis on percutaneous selective portal vein embolization for primary liver cancer[Article in Chinese].Zhonghua Yi Xue Za Zhi 2013;93:3831-3834.PMID:24548443 doi:10.3760/cma.j.issn.0376-2491.2013.48.006.

Monographic series

Davidoff RA.Migraine:manifestations,pathogenesis,and management.Philadelphia,Pa:FA Davis;1995.Contemporary Neurology Series,No.42.

Online journals with volume and page information

Simon JA,Hudes ES.Relationship of ascorbic acid to blood lead levels.JAMA 1999;281:2289-2293.PMID:10386552.Accessed June 11,2009.http://jama.ama-assn.org/cgi/content/full/281/24/2289

Online journals without volume and page information

Li JH,Jia JJ,Shen W,Chen SS,Jiang L,Xie HY,et al.Optimized postconditioning algorithm protects liver graft after liver transplantation in rats.Hepatobiliary Pancreat Dis Int 2018 Feb 2.PMID:29428101 doi:10.1016/j.hbpd.2018.01.006.

Online website

Morse SS. Factors in the emergence of infectious diseases.Emerg Infect Dis[serial online]1995 Jan-Mar[cited 1996 Jun 5];1(1):[24 screens].Available from:www.cdc.gov/ncidod/eid/vol1no1/morse.htm

Book—more than one author(list all authors if six or less,otherwise list first three followed by et al)

Baselt RC,Cravey RH.Disposition of toxic drugs and chemicals in man,4th ed.Foster City,CA:Chemical Toxicology Institute;1995.

Chapter from a book

Calne RY. Experimental background. In: Calne RY, ed. Liver transplantation,2nd ed.London:Grune&stratton;1987:3-7.

Book—with editors

Maddrey WC,ed.Transplantation of the liver.New York:Elsevier Science Publishing;1998.

IllustrationsPhotographs,drawings,diagrams,charts and graphs should meet the editorial demands.The “three-dimensional”bar charts produced by computer programs are not acceptable.Photomicrographs with no inset scale should have the magnification of the print in the caption;stains should be indicated.The lettering on diagrams and graphs should be large enough to be clear after it has been reduced for printing and be consistent in size and style.Color will be accepted only where it is essential.Permission to reproduce any borrowed illustration must be obtained from the author and the publisher,and evidence of this permission must accompany the submitted article.

Review articlesare welcome especially systematic,critical assessments of the literature and data sources pertaining to clinical topics, emphasizing factors such as cause, diagnosis, prognosis,therapy,or prevention.All articles and data sources reviewed should include information about the specific type of study or analysis,population,intervention,exposure,and tests or outcomes.All articles or data sources should be selected systematically for inclusion in the review and critically evaluated,and the selection process should be described in the article.Meta-analyses also will be considered as review articles.Editors ask potential authors of review articles to check the MOOSE initiative for meta-analysis of observational studies in epidemiology(See the appendix).

The articles in department ofNew techniquesfocus on the new techniques used,which are of interest to clinicians and researchers.Clinical images,clear and interesting,are submitted with descriptive paragraph of 500-800 words.Authors must obtain signed informed consent from the patient.

Viewpointsmay address virtually any important topic in the fields of hepatobiliary and pancreatic diseases,medical,surgical,radiological,pathological,biochemical,physiological and histological aspects,and generally are not linked to a specific article.It can be up to 1500 words,two tables or figures,no more than 10 references and 6 authors.

Letters to the editoron matters of recently published articles in the journal are especially welcome,which should not exceed 400 words.Letters of general interest,unlinked to items published in the journal,can be up to 1500 words long and are to be sent for peer-reviewed.Correspondence letters are not usually peer reviewed,but the journal might invite replies from the authors of the original publication,or pass on letters to these authors.Only two tables or figures are permitted,and there should be no more than 10 references and six authors.All accepted letters are edited,and proofs will be sent out to authors before publication.

Appendix.Reporting guidelines for study designs

Notes,news or announcementsfor conferences,symposia or meetings may be sent for publication at least 3 months before the required date of publication.These are mostly included under Meetings and Courses without payment.Provide title,date(s)and place of the event and contact address,telephone,and E-mail address.Hepatobiliary&Pancreatic Diseases International reserves the right to be selective in publishing these announcements.Those wishing for a detailed publication may submit as advertisements.For academic information,subsidized rates are available.

Letter of copyright transfer

We require a letter of copyright transfer signed by all named authors,stating that they have taken a significant and active part in the preparation of the article,that they have read and approved the final version,and are willing to discuss it in detail.This is essential for the reviewing process to be completed.Possibly duplicative materials(i.e.,those containing substantially similar content or using the same or similar data)that have been previously published or are being considered elsewhere must be provided at the time of manuscript submission.

To conform with the Copyright Act of China,this letter must contain the following paragraph:

In consideration of Hepatobiliary&Pancreatic Diseases International reviewing and editing my(our)submission,the author(s)undersigned hereby transfer(s), assign(s), or otherwise conveys all copyright ownership to Hepatobiliary & Pancreatic Diseases International represent(s)that he(they)own(s)all rights in the material submitted.The author(s)further confirm(s)that the article is original,that it is not under consideration by another journal in any language,and that it has not been previously published,in whole or in part,in another journal in any language.There is no conflict of interests relevant to the study reported in this article.

For convenience potential author can download the form of the letter from our journal's website.This assignment is to take effect only if the work is accepted for publication in Hepatobiliary &Pancreatic Diseases International.

These instructions can also be found on the journal's website at www.hbpdint.com and may be copied by those intending to submit an article.

Letter of Copyright Transfer

We have taken a significant and active part in the preparation of the article,and we have read and approved the final version.We are willing to discuss it in detail.

In consideration of Hepatobiliary&Pancreatic Diseases International reviewing and editing my(our)submission,the author(s)undersigned hereby transfer(s),assign(s),or otherwise conveys all copyright ownership to Hepatobiliary&Pancreatic Diseases International represent(s)that he(they)own(s)all rights in the material submitted.The author(s)further confirm(s)that the article is original,that it is not under consideration by another journal in any language,and that it has not been previously published,in whole or in part,in another journal in any language.There is no conflict of interests relevant to the study reported in this article.

This assignment is to take effect only if the work is accepted for publication in Hepatobiliary&Pancreatic Diseases International.Authors'name(s)in order of appearance in the manuscript,signatures(date):

Announcements for this section should be submitted in the correct format at least 3 months before the required date of publication. This list is provided as a service to readers; inclusion does not imply endorsement by the Hepatobiliary &Pancreatic Diseases International.

Section editor

Shui-Ying Lei

Email: hbpdint@126.com

June

EORTC-ESMO-AACR methods in clinical cancer research

June 26-July 2, 2020; De Ruwenberg,Sint-Michielsgestel, Netherlands

The workshop is organized by the European Organisation of Research and Treatment of Cancer (EORTC), European Society for Medical Oncology (ESMO), and American Association for Cancer Research(AACR). The annual methods in clinical cancer research workshop is a week-long course designed to educate and train early-career investigators in the best practices of clinical trial design and provide access to experienced clinical investigators from different institutions and countries with expertise across all areas of clinical research. The workshop is offered to early-career investigators in all disciplines working the field of oncology who are nearing completion of their training or have recently begun their initial faculty positions and is designed to address the needs today, while maintaining flexibility to implement changes to train early-career investigators on how to conduct effective clinical trials in the future. In addition, it enables the development of peer-to-peer and mentoring relationships to enhance future career development. For more information, please visit: https://event.eortc.org/mccr2020/ .

July

Molecular biology in clinical oncology workshop

July 19-26, 2020; Viceroy Snowmass, Snowmass Village, Colorado

Workshop director is Ross L. Levine, Memorial Sloan Kettering Cancer Center, New York, New York; and workshop codirectors are Mark W. Geraci, Indiana University, Indianapolis, Indiana;Christine M. Lovly, Vanderbilt University School of Medicine,Nashville, Tennessee; and Jean Y. Tang, Stanford University School of Medicine, Redwood City, California. This is an intensive workshop providing a substantive overview of molecular biology, translational cancer research, current lab techniques,career development, and the best practices of grant writing for the aspiring physician-scientist. For more information, please visit: https://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=229 .

AACR/ASCO methods in clinical cancer research workshop

July 25 - 31, 2020; Vail Marriott Mountain Resort,Vail, Colorado

Workshop codirectors are Manuel Hidalgo, Weill Cornell Medicine,New York Presbyterian Hospital, New York, New York; Julie M.Vose, University of Nebraska Medical Center, Omaha, Nebraska; and Thomas Braun, University of Michigan Comprehensive Cancer Center,Ann Arbor, Michigan. This is an intensive workshop in the essentials of effective clinical trial designs of therapeutic interventions in the treatment of cancer for clinical fellow and junior faculty clinical researchers in all oncology subspecialties, including radiation and surgical oncology and radiology. For further information, please contact Kathryn Leonard, PhD, Workshop Adminitrator, at 215-309-4356 or kathryn.leonard@aacr.org; Website: https://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=230 .

HBP surgery week 2020 & the 52nd annual congress of the Korean Association of HBP Surgery

July 27-29, 2020; Seoul Dragon City, Seoul, Korea

Under the slogan, a??A Leap from the Foundation to Fine Art,a?? HBP surgery week 2020 will mark a new stage in the history as the fruits of hard work transcend beyond mere technical skills into a veritable art form. The committee will concentrate all the effort s into making this congress a most valuable experience for all surgeons, nurses,basic researchers, young investigators, students, and professionals who have a dedicated interest in HBP Surgery research and care. For further information, please visit http://www.khbps.org/html/ .